{"url_path":"/sec/nnvc/8-k/2026-07-17/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-084668-index.html","accession_number":"0001104659-26-084668","cik":"0001379006","ticker":"NNVC","issuer_name":"NANOVIRICIDES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1379006/0001104659-26-084668-index.html","primary_entity_key":"0001379006","primary_entity_name":"NANOVIRICIDES, INC."},"word_count":501,"has_tables":true,"body_markdown":"**Item 1.01. Entry into a Material Definitive\nAgreement.**\n\n \n\nOn July 17, 2026, NanoViricides, Inc., a Delaware\ncorporation (the “Company”), entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with D.\nBoral Capital LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, through or to\nthe Sales Agent, shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), in an “at\nthe market” offering as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”). \n\n \n\nOn July 17, 2026, the Company filed a prospectus\nsupplement with the U.S. Securities and Exchange Commission (the “Commission”) in connection with the Sales Agreement (the\n“Prospectus Supplement”) under its existing shelf Registration Statement on Form S-3 (File No. 333-296550) (the “Registration\nStatement”) initially filed with the Commission on June 5, 2026 and declared effective on June 15, 2026, and the base prospectus\nincluded therein. \n\n \n\nSales of Common Stock, if any, may be made by\nany method permitted by law deemed to be an “at the market” offering, including sales made directly on the NYSE American or\non any other existing trading market for the Common Stock. The Sales Agent may also sell shares of Common Stock by any other method permitted\nby law, including in privately negotiated transactions, with the Company’s prior written consent.\n\n \n\nThe Company will instruct the Sales Agent as to\nthe parameters of each sale of shares of Common Stock under the Sales Agreement by delivery of a placement notice. The Sales Agent will\nuse its best efforts consistent with its normal trading and sales practices and applicable law to sell shares of Common Stock under the\nSales Agreement on the terms and subject to the conditions set forth therein. The Company has agreed to pay the Sales Agent a commission\nequal to 2.0% of the aggregate gross proceeds from each sale of shares of Common Stock sold through the Sales Agent under the Sales Agreement.\nThe shares of Common Stock that may be offered and sold pursuant to the Sales Agreement (the “Placement Shares”) will be issued\nand sold pursuant to the Registration Statement and the Prospectus Supplement.  The offer and sale of the Placement Shares pursuant\nto the Sales Agreement will terminate upon the earlier of (a) the issuance and sale of all of the Placement Shares subject to the\nSales Agreement or (b) the termination of the Sales Agreement by the Company or the Sales Agent pursuant to the terms thereof.\n\n \n\nThe foregoing description of the Sales Agreement\ndoes not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, which is filed\nas Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nA copy of the opinion of Lucosky Brookman LLP\nrelating to the validity of the Placement Shares that may be sold pursuant to the Sales Agreement is filed herewith as Exhibit 5.1."}